Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | PPARD | Q03181 | 1/20 | 0.42 |
| ▸ | LPAR3 | Q9UBY5 | 5/20 | 0.41 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.41 |
| ▸ | LPAR2 | Q9HBW0 | 3/20 | 0.41 |
| ▸ | CES2 | O00748 | 3/20 | 0.40 |
| ▸ | CES1 | P23141 | 3/20 | 0.40 |
| ▸ | LPAR6 | P43657 | 1/20 | 0.40 |
| ▸ | LPAR4 | Q99677 | 1/20 | 0.40 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.40 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.40 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.39 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4942146 | 0.98 | MAPT (0.46) | MAPTKMT2APPARDLPAR3LPAR1 | |
| SCHEMBL7714481 | 0.94 | PPARD (0.44) | PPARDLPAR3LPAR1LPAR2CES2 | |
| SCHEMBL8581475 | 0.83 | MAPT (0.44) | MAPTKMT2APPARDCES2CES1 | |
| SCHEMBL7616579 | 0.83 | KMT2A (0.44) | MAPTKMT2APPARDCES2CES1 | |
| SCHEMBL11875238 | 0.82 | TSHR (0.49) | MAPTKMT2ALPAR3LPAR1LPAR2 | |
| SCHEMBL10431817 | 0.81 | KMT2A (0.47) | MAPTKMT2APPARDCES2CES1 | |
| SCHEMBL4942141 | 0.81 | KMT2A (0.47) | MAPTKMT2APPARDCES2CES1 | |
| SCHEMBL9620427 | 0.80 | TSHR (0.51) | MAPTKMT2ALPAR3LPAR1LPAR2 | |
| SCHEMBL3002275 | 0.78 | KMT2A (0.50) | MAPTKMT2APPARDLPAR3LPAR2 | |
| SCHEMBL3929518 | 0.76 | PPARD (0.41) | PPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4052407-A | ENZYME INHIBITORS, MULTISTAGE | GYOGYSZERKUTATO INTEZET (HU) | 1977-10-04 | — | — | US | claimed |
| US-20190248725-A1 | PROCESS FOR THE PREPARATION OF TREPROSTINIL | CHINOIN Gyógyszer és Vegyészeti Termékek Gyára Zrt. (HU) | 2019-08-15 | — | — | US | disclosed |
| US-10322990-B2 | Process for the preparation of treprostinil | CHINOIN Gyógyszer és Vegyészeti Termékek Gyára Zrt. (HU) | 2019-06-18 | — | — | US | disclosed |
| US-20170313643-A1 | PROCESS FOR THE PREPARATION OF TREPROSTINIL | CHINOIN Gyógyszer és Vegyészeti Termékek Gyára Zrt. (HU) | 2017-11-02 | — | — | US | disclosed |
| EP-3204349-A1 | PROCESS FOR THE PREPARATION OF TREPROSTINIL | Chinoin Gyógyszer és Vegyészeti Termékek Gyára Zrt. (HU) | 2017-08-16 | — | — | EP | disclosed |
| WO-2016055819-A1 | PROCESS FOR THE PREPARATION OF TREPROSTINIL | CHINOIN Gyógyszer és Vegyészeti Termékek Gyára Zrt. (HU) | 2016-04-14 | — | — | WO | disclosed |
| EP-2001849-B1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2014-11-26 | — | — | EP | disclosed |
| EP-2468727-A1 | Pyridine and pyrimidine derivatives as MGLUR2 antagonists | F. Hoffmann-La Roche AG (CH) | 2012-06-27 | — | — | EP | disclosed |
| US-8183262-B2 | Central nervous system disorders; metabotropic glutamate receptors (mGluR); 2-(4-Pyridin-3-yl-imidazol-1-yl)-4-trifluoromethyl-6-(4-trifluoromethyl-phenyl)-pyrimidine | HOFFMANN-LA ROCHE INC. (US) | 2012-05-22 | — | — | US | disclosed |
| US-7642264-B2 | Phenyl-substituted pyrimidine derivatives as mGluR antagonists | HOFFMAN-LA ROCHE INC. (US) | 2010-01-05 | — | — | US | disclosed |
| EP-2001849-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS | F. Hoffmann-Roche AG (CH) | 2008-12-17 | — | — | EP | disclosed |
| US-20070232583-A1 | Pyridine and pyrimidine derivatives as mGIuR2 antagonists | HOFFMANN-LA ROCHE INC. | 2007-10-04 | — | — | US | disclosed |
| WO-2007110337-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-10-04 | — | — | WO | disclosed |
| US-5625067-A | Cyclopentane ether derivatives, processes for their production, and their pharmaceutical use | SCHERING AKTIENGESELLSCHAFT (DE) | 1997-04-29 | — | — | US | disclosed |
| US-4692464-A | Novel prostacyclin derivatives and a process for the preparation thereof | SCHERING AKTIENGESELLSCHAFT (DE) | 1987-09-08 | — | — | US | disclosed |
| US-4610999-A | ANTICOAGULANTS, HYPOTENSIVE | HOECHST AKTIENGESELLSCHAFT (DE) | 1986-09-09 | — | — | US | disclosed |
| US-4611000-A | ANTICOAGULANTS, HYPOTENSIVE | HOECHST AKTIENGESELLSCHAFT (DE) | 1986-09-09 | — | — | US | disclosed |
| US-4359581-A | Process for the production of caracyclin intermediates | SCHERING AG (DE) | 1982-11-16 | — | — | US | disclosed |
| US-4309407-A | ANTIINFLAMMATORY, ANTIPYRETIC, ANTI-ARTERIOSCLEROTIC | A. NATTERMANN & CIE. GMBH (DE) | 1982-01-05 | — | — | US | disclosed |
| US-4052407-A | ENZYME INHIBITORS, MULTISTAGE | GYOGYSZERKUTATO INTEZET (HU) | 1977-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10322990-B2 | Process for the preparation of treprostinil | PTGIS, PTGIR, THPO | MAPT 3990/4885KMT2A 4728/4885PPARD 1371/4885 |
| US-20070232583-A1 | Pyridine and pyrimidine derivatives as mGIuR2 antagonists | P2RX2, P2RY2, P2RX1 | MAPT 658/4885KMT2A 2308/4885PPARD 2070/4885 |
| US-20190248725-A1 | PROCESS FOR THE PREPARATION OF TREPROSTINIL | PTGIS, TFPI, TREH | MAPT 4253/4885KMT2A 4557/4885PPARD 2033/4885 |
| US-20170313643-A1 | PROCESS FOR THE PREPARATION OF TREPROSTINIL | PTGIS, CYP2C19, CYP2F1 | MAPT 3440/4885KMT2A 3776/4885PPARD 2638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.